Capricor Therapeutics
CAPR
20 hedge funds and large institutions have $2.57M invested in Capricor Therapeutics in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 4 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0.45% more ownership
Funds ownership: 0% → 0.45% (+0.45%)
9% less funds holding
Funds holding: 22 → 20 (-2)
23% less capital invested
Capital invested by funds: $3.34M → $2.57M (-$769K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$65.3K |
| 2 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
+$59.9K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$43.7K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$42.9K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.07K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
Apriem Advisors
Irvine,
California
|
-$230K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$93K |
| 3 |
Goldman Sachs
New York
|
-$75.7K |
| 4 |
Morgan Stanley
New York
|
-$7.49K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
CAPR Hedge Fund Activity: Q4 2016 in Review
20 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q4 2016, worth a combined $2.57M — down 23% from $3.34M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CAPR and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $65.3K. The largest seller was Apriem Advisors, exiting entirely with an estimated $230K sold.
- 20 institutional investors held Capricor Therapeutics (CAPR) as of Q4 2016, down from 22 in Q3 2016.
- Funds reported $2.57M of Capricor Therapeutics stock for Q4 2016, down 23% quarter-over-quarter.
- 2 funds opened new Capricor Therapeutics positions in Q4 2016 and 4 closed out, a net change of -2 holders.
- The largest Capricor Therapeutics buyer in Q4 2016 was Vanguard Group, an estimated $65.3K added.
- The largest Capricor Therapeutics seller in Q4 2016 was Apriem Advisors, an estimated $230K sold.
Based on aggregated 13F filings for Q4 2016.